Stifel Nicolaus Lowers Avanos Medical (NYSE:AVNS) to Hold

Stifel Nicolaus lowered shares of Avanos Medical (NYSE:AVNS) from a buy rating to a hold rating in a research note published on Wednesday, AnalystRatings.com reports. Stifel Nicolaus currently has $35.00 price target on the stock, down from their previous price target of $45.00.

A number of other equities research analysts have also recently issued reports on AVNS. Zacks Investment Research upgraded Avanos Medical from a sell rating to a hold rating and set a $46.00 price objective for the company in a report on Wednesday, October 30th. Raymond James downgraded shares of Avanos Medical from an outperform rating to a market perform rating in a research report on Wednesday. ValuEngine downgraded shares of Avanos Medical from a strong-buy rating to a buy rating in a research report on Tuesday, November 5th. Finally, JMP Securities restated a hold rating on shares of Avanos Medical in a research report on Wednesday, August 21st. Two analysts have rated the stock with a sell rating, four have assigned a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $44.80.

Shares of NYSE AVNS traded up $1.61 during mid-day trading on Wednesday, hitting $35.54. The company had a trading volume of 433,684 shares, compared to its average volume of 336,622. The company has a market capitalization of $1.77 billion, a PE ratio of 43.34 and a beta of 1.56. The firm has a 50-day simple moving average of $39.33 and a two-hundred day simple moving average of $39.95. The company has a current ratio of 3.06, a quick ratio of 2.35 and a debt-to-equity ratio of 0.25. Avanos Medical has a one year low of $31.78 and a one year high of $53.45.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, November 5th. The company reported $0.30 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.32 by ($0.02). Avanos Medical had a negative net margin of 6.20% and a positive return on equity of 3.91%. The company had revenue of $171.40 million during the quarter, compared to the consensus estimate of $179.98 million. During the same quarter in the previous year, the business earned $0.37 EPS. Avanos Medical’s revenue was up 3.8% on a year-over-year basis. Sell-side analysts expect that Avanos Medical will post 1.05 earnings per share for the current fiscal year.

Several large investors have recently modified their holdings of AVNS. BlackRock Inc. grew its holdings in shares of Avanos Medical by 0.4% in the 2nd quarter. BlackRock Inc. now owns 5,465,732 shares of the company’s stock worth $238,360,000 after acquiring an additional 23,000 shares during the last quarter. Victory Capital Management Inc. increased its stake in shares of Avanos Medical by 4.3% in the second quarter. Victory Capital Management Inc. now owns 2,291,582 shares of the company’s stock worth $99,936,000 after purchasing an additional 94,857 shares during the period. Paradice Investment Management LLC increased its stake in shares of Avanos Medical by 12.9% in the third quarter. Paradice Investment Management LLC now owns 2,248,108 shares of the company’s stock worth $84,214,000 after purchasing an additional 256,525 shares during the period. Invesco Ltd. increased its stake in shares of Avanos Medical by 21.0% in the second quarter. Invesco Ltd. now owns 1,637,165 shares of the company’s stock worth $71,396,000 after purchasing an additional 284,234 shares during the period. Finally, Northern Trust Corp increased its stake in Avanos Medical by 6.7% during the second quarter. Northern Trust Corp now owns 1,371,355 shares of the company’s stock valued at $59,805,000 after acquiring an additional 85,694 shares during the period. Institutional investors and hedge funds own 94.14% of the company’s stock.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life worldwide. It provides a portfolio of products focuses on respiratory and digestive health; pain management solutions; and minimally invasive interventional pain therapies, closed airway suction systems, and enteral feeding tubes.

Read More: What is Green Investing?

Analyst Recommendations for Avanos Medical (NYSE:AVNS)

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.